Search alternatives:
ns decrease » nn decrease (Expand Search), _ decrease (Expand Search), use decreased (Expand Search)
mg decrease » _ decrease (Expand Search), nn decrease (Expand Search), mean decrease (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), mean decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
50 ns » 50 ms (Expand Search)
ns decrease » nn decrease (Expand Search), _ decrease (Expand Search), use decreased (Expand Search)
mg decrease » _ decrease (Expand Search), nn decrease (Expand Search), mean decrease (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), mean decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
50 ns » 50 ms (Expand Search)
-
21
Olaparib reverses the oxLDL-mediated decrease in co-immunoprecipitation of IκBα with RelA or p50.
Published 2024“…Relative band densities from three independent experiments were analyzed. (A) OxLDL decreased co-immunoprecipitation of IκBα with both RelA and p50, and olaparib reversed the effect of oxLDL on the dissociation of IκBα with RelA and p50. …”
-
22
-
23
Image_1_Decrease in Serum Urate Level Is Associated With Loss of Visceral Fat in Male Gout Patients.tif
Published 2021“…Subjects included had all been treated with urate-lowering therapy (ULT) (febuxostat 20–80 mg/day or benzbromarone 25–50 mg/day, validated by the medical record). …”
-
24
-
25
-
26
FTY720 treatment decreased tumor growth in a xenograft model of hepatoblastoma.
Published 2019“…When tumors reached an average of 150 mm<sup>3</sup>, mice were randomized to receive vehicle (ORA-Plus, 50 μL, n = 7) or FTY720 (10 mg/kg body weight/day in ORA-Plus, 50 μL, n = 7) by oral gavage for 16 days. …”
-
27
-
28
-
29
-
30
-
31
DataSheet_1_Decrease in Serum Urate Level Is Associated With Loss of Visceral Fat in Male Gout Patients.docx
Published 2021“…Subjects included had all been treated with urate-lowering therapy (ULT) (febuxostat 20–80 mg/day or benzbromarone 25–50 mg/day, validated by the medical record). …”
-
32
-
33
-
34
-
35
-
36
-
37
-
38
-
39
-
40